RecruitingNot ApplicableNCT04451915

Early Gestational Diabetes Mellitus

Late Versus Early Management of Gestational Diabetes Mellitus: a Non Inferiority Randomized Multicenter Trial


Sponsor

University Hospital, Lille

Enrollment

2,010 participants

Start Date

Nov 30, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

In 2010, the International Association of the Diabetes and Pregnancy Study Groups (IADPSG) panel published consensus-based recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Cognizant that milder degrees of hyperglycemia would also be detected by early pregnancy testing, the IADPSG recommended that fasting plasma glucose (FPG) in the range of 5.1-6.9 mmol/l should be considered diagnostic of early Gestational Diabetes Mellitus (GDM) even if the level of proof for this recommendation is very low regarding to prognosis. This threshold was extrapolated from the FPG value used between 24 and 28 weeks. In France, a FPG is proposed at the first prenatal visit for women with risk factors of GDM. Early GDM is diagnosed if FPG is ≥ 5.1 mmol/l, leading to an intensive metabolic management. Data have shown that GDM prevalence increased rapidly from 5.9% in 2009 to 9.3% in 2014. 26.9% of women with hyperglycemia during their pregnancy but without known diabetes are treated before 22 weeks' gestation (WG). More recent data from Italy and China, where IADPSG diagnosis criteria were applied, have strongly challenged this recommendation, and showed that early FPG ≥ 5.1mmo/L is poorly predictive of later GDM. No prior studies have demonstrated benefits to early screening and management. In 2016, the IADPSG members have suggested that the use of the FPG threshold ≥5.1 mmol/l for the identification of GDM in early pregnancy is not justified by current evidence


Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying early management strategy and late management strategy for people with gestational diabetes. The study is currently recruiting participants at 10 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERlate management strategy

late management strategy of GDM defined as no intervention until GDM screening at 24-28 weeks. Between 24-28 weeks gestation, a 75-g OGTT will be done

OTHERearly management strategy

early management of GDM defined as intensive metabolic treatment. Intensive treatment involved the following multidisciplinary approach: lifestyle defined by diet and exercise intervention according to the French guidelines


Locations(10)

CH ARRAS

Arras, France

Hopital Estaing - Chu63 - Clermont Ferrand

Clermont-Ferrand, France

Hop Claude Huriez Chu Lille

Lille, France

Hopital Saint Vincent - Saint Antoine - Lille

Lille, France

Chu Nimes Caremeau - Nimes 9

Nîmes, France

Hopital Haut-Leveque - Chu - Pessac

Pessac, France

Ch Rene Dubos - Pontoise

Pontoise, France

Chu Site Sud (Saint Pierre) - St Pierre

Saint-Pierre, France

Csapa / Hus / Hopital Civil - Strasbourg

Strasbourg, France

Hopital de Rangueil Chu Toulouse

Toulouse, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04451915


Related Trials